Protagonist Therapeutics (PTGX)Exceeds Revenue Estimates in Q3 2024
Protagonist Therapeutics Inc. (PTGX) is an innovative clinical-stage biopharmaceutical…
Protagonist Therapeutics (PTGX)Exceeds Revenue Estimates in Q3 2024
Protagonist Therapeutics Inc. (PTGX) is an innovative clinical-stage biopharmaceutical company that specializes in the discovery and development of…
Madrigal Pharmaceuticals (MDGL): A Financial Powerhouse With $1.0 Billion Cash Position in 2024
Madrigal Pharmaceuticals Inc. (MDGL) is a pioneering biopharmaceutical company focused on developing and commercializing novel, life-changing therapies for…
Kamada (KMDA) Reports Strong Q3 2024 Financial Results with $41.7M in Revenue
Kamada Ltd. (KMDA) is a prominent global biopharmaceutical company that has established itself as a leader in the…
Gossamer Bio (GOSS) Reports Strong Q3 2024 Financial Results
Gossamer Bio Inc. (GOSS) is a prominent clinical-stage biopharmaceutical company based in San Diego, California, committed to the…
Lakeside (LSH) Partners with Huiyu Pharmaceutical to Expand Global Oncology Drug Distribution
Lakeside Holding Limited (LSH) is a dynamic U.S.-based cross-border supply chain solution provider, strategically headquartered in Itasca, Illinois.…
Sanara MedTech (SMTI) Achieves Record $21.7M Revenue in Q3 2024
Sanara MedTech Inc. (SMTI), headquartered in Fort Worth, Texas, is a leading medical technology company dedicated to developing…
Aldeyra (ALDX) Reports $15.1M Q3 2024 Loss Amid R&D Investments
Aldeyra Therapeutics Inc. (ALDX) is a clinical-stage biotechnology company that stands at the forefront of innovation in addressing…
Galectin (GALT) Reports Improved Financial Performance in Q3 2024
Galectin Therapeutics Inc. (GALT) is a pioneering biopharmaceutical company dedicated to developing innovative therapies that target galectin proteins,…
Health In Tech (HIT) Achieves $289.8M Market Cap with Robust Growth Potential
Health In Tech Inc. (HIT) is a leading innovator in the Insurtech industry, specializing in technology-driven solutions that…
Septerna (SEPN) Raises $302.6 Million in IPO to Fuel Drug Development Pipeline
Septerna Inc. (SEPN) is a clinical-stage biotechnology company revolutionizing drug discovery through its proprietary Native Complex Platform™, which…
BioLineRx (BLRX)’s APHEXDA Captures 10% Market Share in U.S. CXCR4 Inhibitors by Q3 2024
BioLineRx Ltd. (BLRX) is a cutting-edge biopharmaceutical company dedicated to developing and commercializing transformative therapies in oncology and…
Synergy (SNYR)’s Strategic Rebranding: A New Era for FOCUSfactor
Synergy CHC Corp. (SNYR) is a leading innovator in the consumer health and lifestyle products industry, delivering scientifically-backed…
Prostate Cancer Breakthrough: Candel Therapeutic (CADL)’s CAN-2409 Trials Near Completion
Candel Therapeutics Inc. (CADL) is a clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through advanced multimodal immunotherapies.…
Monopar Therapeutics (MNPR) Strengthens Financial Stability with $17.7M Public Offering
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for rare diseases…
Tectonic Therapeutic Reports Strong Q3 2024 Financial Results, $159.1M Cash Reserves
Tectonic Therapeutic Inc. (TECX) is a cutting-edge biotechnology company dedicated to pioneering advancements in the discovery and development…
Innoviva (INVA)’s Expanding Portfolio Drives 33% Revenue Growth in Q3 2024
Innoviva Inc. (INVA) is a forward-thinking healthcare company dedicated to advancing medical innovation and improving patient outcomes worldwide.…
Collegium (COLL) Reports $9.3M Net Income in Q3 2024 with Record-Breaking Product Sales
Collegium Pharmaceutical Inc. (COLL) is a trailblazer in the specialty pharmaceutical industry, dedicated to improving the lives of…
Arcutis (ARQT) Achieves $44.8M in Q3 2024 Revenue, Growing 452% Year-Over-Year
Arcutis Biotherapeutics Inc. (ARQT) is a commercial-stage biopharmaceutical company dedicated to revolutionizing the treatment of immune-mediated skin diseases.…